Search

Your search keyword '"Antimitotic agents -- Conferences, meetings and seminars"' showing total 58 results
Start Over Descriptor "Antimitotic agents -- Conferences, meetings and seminars" Publisher comtex news network, inc.
58 results on '"Antimitotic agents -- Conferences, meetings and seminars"'

1. Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Subjects
Qualigen Therapeutics Inc. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Societies -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Cancer -- Research, Associations, institutions, etc. -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars -- Drug therapy, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. ('Qualigen' or the 'Company,' Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel [...]

Published
2024

2. Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Subjects
United States. Food and Drug Administration -- Conferences, meetings and seminars, Tyrosine -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Stomach cancer -- Conferences, meetings and seminars, Drug approval -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

BOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase' or 'Company'), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course [...]

Published
2024

3. Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

Preclinical data highlights ciforadenant's mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues in Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic [...]

Published
2023

4. Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Pulmonary hypertension -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing Formulation impacted lung exposure with dry powder demonstrating greater lung [...]

Published
2023

5. Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference

Subjects
Biological products industry -- Conferences, meetings and seminars -- Officials and employees, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Drug therapy -- Conferences, meetings and seminars, Fibroblast growth factors -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

SAN FRANCISCO and SAN DIEGO, Sep 13, 2021 (GLOBE NEWSWIRE via COMTEX) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) ('Kinnate'), a biopharmaceutical company focused on the discovery and development of small [...]

Published
2021

6. IN8bio Presents Gamma-Delta T Cells as Cancer Therapeutics at the ESMO Targeted Anticancer Therapies Virtual Conference 2021

Subjects
T cells -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Immunotherapy -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Drug therapy -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEW YORK, March 02, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- IN8bio, Inc. ('IN8bio' or the 'Company'), a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies, [...]

Published
2021

7. ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma

Subjects
ADC Therapeutics S.A. -- Conferences, meetings and seminars, Biopharmaceutics -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Diseases -- Relapse, Drug discovery -- Conferences, meetings and seminars, Viral antibodies -- Conferences, meetings and seminars, Non-Hodgkin's lymphomas -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Antibodies -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

LAUSANNE, Switzerland, Jun 21, 2019 (GLOBE NEWSWIRE via COMTEX) -- Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to [...]

Published
2019

8. OncoMed Pharmaceuticals Updates Phase 1b Data for Demcizumab With Pemetrexed and Carboplatin in Patients With First-Line Stage IIIb/IV Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Lung cancer, Non-small cell -- Conferences, meetings and seminars -- Care and treatment, Chemotherapy -- Conferences, meetings and seminars, Cancer -- Chemotherapy, Monoclonal antibodies -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, Calif., Oct 20, 2013 (GLOBE NEWSWIRE via COMTEX) -- Safety Profile of Novel Combination Consistent With Known Toxicities of Demcizumab and Chemotherapy; No New Safety Signals Early Evidence [...]

Published
2013

9. Basilea presents first phase 1 data from its novel anti-cancer drug BAL101553 at ASCO conference

Subjects
Thomson Reuters Corp. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Information services industry -- Conferences, meetings and seminars, Cancer -- Care and treatment, Information services -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Information services industry, Business, international, American Society of Clinical Oncology -- Conferences, meetings and seminars
Abstract

(Thomson Reuters ONE via COMTEX) -- Basilea Pharmaceutica AG / Basilea presents first phase 1 data from its novel anti-cancer drug BAL101553 at ASCO conference . Processed and transmitted by [...]

Published
2013

10. Basilea presents first phase 1 data from its novel anti-cancer drug BAL101553 at ASCO conference

Subjects
Thomson Reuters Corp. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Information services industry -- Conferences, meetings and seminars, Cancer -- Care and treatment, Information services -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Information services industry, Business, Business, international, News, opinion and commentary, American Society of Clinical Oncology -- Conferences, meetings and seminars
Abstract

Byline: BASEL, SWITZERLAND, Jun 04, 2013 (Marketwired via COMTEX) -- Basilea Pharmaceutica AG / Basilea presents first phase 1 data from its novel anti-cancer drug BAL101553 at ASCO conference. Processed [...]

Published
2013

11. ZIOPHARM Oncology to Participate in the 2012 Deutsche Bank BioFEST Conference

Subjects
Deutsche Bank AG (Frankfurt, Germany) -- Conferences, meetings and seminars, Banks (Finance) -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Banking industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking industry, Banking, finance and accounting industries, Business
Abstract

Byline: Staff NEW YORK, Nov 28, 2012 (GlobeNewswire via COMTEX) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 2012 [...]

Published
2012

12. Basilea's novel oncology drug candidate BAL101553: data presented at international conference demonstrate dual mode of action

Subjects
Thomson Reuters Corp. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Information services industry -- Conferences, meetings and seminars, Cancer -- Care and treatment, Information services -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Information services industry, Business, international
Abstract

(Thomson Reuters ONE via COMTEX) -- Basilea Pharmaceutica AG / Basilea's novel oncology drug candidate BAL101553: data presented at international conference demonstrate dual mode of action . Processed and transmitted [...]

Published
2012

13. MethylGene Presents MGCD265 Data at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting

Subjects
MethylGene Inc. -- Conferences, meetings and seminars, Endothelial growth factors -- Conferences, meetings and seminars, Trade and professional associations -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Vascular endothelial growth factor -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Business, international, News, opinion and commentary
Abstract

Byline: MONTREAL, CANADA, Jun 04, 2012 (MARKETWIRE via COMTEX) -- MethylGene Inc. (TSX: MYG) today announced that clinical data for its Met/VEGFR multi- kinase inhibitor MGCD265 was presented in a [...]

Published
2012

14. Threshold Pharmaceuticals' TH-302 to Be Featured at Symposium on Hypoxia in Cancer Hosted by the New York Academy of Sciences

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Business, international, News, opinion and commentary
Abstract

Byline: SOUTH SAN FRANCISCO, CA, Mar 12, 2012 (MARKETWIRE via COMTEX) -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) announced that TH-302 will be featured among several presentations by academic and industry [...]

Published
2012

15. Novel Findings for Molecular Profiling of Head and Neck Squamous Cell Carcinoma (HNSCC) Presented at the 2012 Multidisciplinary Head & Neck Cancer Symposium

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Squamous cell carcinoma -- Conferences, meetings and seminars, Cancer -- Care and treatment, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

Byline: Staff IRVING, Texas, Feb 2, 2012 (GlobeNewswire via COMTEX) -- Caris Life Sciences(TM), Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality [...]

Published
2012

16. Threshold Pharmaceuticals Announces Update to TH-302 Pancreatic Data to Be Presented at the Oppenheimer Healthcare Conference

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Health care industry, Business, Business, international, News, opinion and commentary
Abstract

Byline: SOUTH SAN FRANCISCO, CA, Dec 13, 2011 (MARKETWIRE via COMTEX) -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to [...]

Published
2011

17. Positive phase IIa bone marker data of Alpharadin in breast cancer patients with bone metastases presented at 2011 San Antonio Breast Cancer Symposium

Subjects
Medical research -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Cancer patients -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Care and treatment, Clinical trials -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, international
Abstract

Oslo, Norway, Dec 09, 2011 (Thomson Reuters ONE via COMTEX) -- Oslo, Norway, 9 December 2011 - Algeta ASA (OSE: ALGETA) announces that positive results from the phase IIa BC1-09 [...]

Published
2011

18. GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

Dec 09, 2011 (M2 PRESSWIRE via COMTEX) -- Improvement in disease-free survival does not reach statistical significance in study of delayed adjuvant therapy with lapatinib (Tykerb or Tyverb) monotherapy in [...]

Published
2011

19. Positive phase IIa bone marker data of Alpharadin in breast cancer patients with bone metastases to be presented at 2011 San Antonio Breast Cancer Symposium

Subjects
Medical research -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Cancer patients -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Care and treatment, Clinical trials -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, international
Abstract

Oslo, Norway, Dec 06, 2011 (Thomson Reuters ONE via COMTEX) -- Oslo, Norway, 6 December 2011 - Algeta ASA (OSE: ALGETA) announces that results from its phase IIa BC1-09 clinical [...]

Published
2011

20. Lorus Therapeutics Presents Positive Data From Nonclinical Toxicity Studies on Lead Cancer Drug at Major Conference

Subjects
Lorus Therapeutics Inc. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Research, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, general, Business, regional
Abstract

TORONTO, ONTARIO, Nov 8, 2011 (Marketwire via COMTEX) -- Lorus Therapeutics Inc. (TSX:LOR) ('Lorus'), today announced the presentation of positive nonclinical toxicity data for its lead small molecule anti-cancer drug [...]

Published
2011

21. Lorus Therapeutics Presents Positive Data From Nonclinical Toxicity Studies on Lead Cancer Drug at Major Conference

Subjects
Oncology, Experimental -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Research, Lung cancer, Non-small cell -- Conferences, meetings and seminars, Drug approval -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, Business, international, News, opinion and commentary
Abstract

Byline: TORONTO, ONTARIO, Nov 08, 2011 (MARKETWIRE via COMTEX) -- Lorus Therapeutics Inc. (TSX: LOR) ('Lorus'), today announced the presentation of positive nonclinical toxicity data for its lead small molecule [...]

Published
2011

22. Genesis Biopharma Concludes Successful Presentation at Aegis Capital Emerging Growth Conference in Las Vegas

Subjects
Biological products industry -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, Business, international, News, opinion and commentary
Abstract

Byline: LOS ANGELES, CA, May 02, 2011 (MARKETWIRE via COMTEX) -- Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer therapies, today announced its Chairman and CEO, Anthony [...]

Published
2011

23. MindUp BioResearch (HIRU) Participates in the Fourth Conference of the Translational Cancer Medicine 2010 (USA), San Francisco, California

Subjects
Oncology, Experimental -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Conferences, meetings and seminars -- Drug therapy -- Research, Antimitotic agents -- Conferences, meetings and seminars, Business, general, Business, regional, American Association for Cancer Research -- Conferences, meetings and seminars
Abstract

BELGRADE, SERBIA, Feb 9, 2011 (Marketwire via COMTEX) -- Hiru Corporation (PINK SHEETS:HIRU) (http://www.hirucorporation.com/), is pleased to announce that researchers from its MindUp BioResearch (www.mindupbioresearch.com), European subsidiary have presented their [...]

Published
2011

24. MindUp BioResearch (HIRU) Participates in the Fourth Conference of the Translational Cancer Medicine 2010 (USA), San Francisco, California

Subjects
Oncology, Experimental -- Conferences, meetings and seminars, Tumor proteins -- Conferences, meetings and seminars -- Development and progression -- Care and treatment, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Conferences, meetings and seminars -- Development and progression -- Care and treatment -- Research, Antimitotic agents -- Conferences, meetings and seminars, Business, Business, international, News, opinion and commentary, American Association for Cancer Research -- Conferences, meetings and seminars
Abstract

Byline: BELGRADE, SERBIA, Feb 09, 2011 (MARKETWIRE via COMTEX) -- Hiru Corporation (PINK SHEETS: HIRU) (http://www.hirucorporation.com/), is pleased to announce that researchers from its MindUp BioResearch (www.mindupbioresearch.com), European subsidiary have [...]

Published
2011

25. CONFERENCES: 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM - 12/12/10 (5 DAY CONFERENCE)

Subjects
Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, AstraZeneca PLC -- Conferences, meetings and seminars, Sanofi S.A. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, American Association for Cancer Research -- Conferences, meetings and seminars
Abstract

Dec 12, 2010 (TheFlyOnTheWall.com via COMTEX) -- CONFERENCES - 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM 12/12/10 (5 DAY CONFERENCE) Managers: Cancer Therapy & Research Center Location: Henry B. [...]

Published
2010

26. CONFERENCES: 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM - 12/12/10 (5 DAY CONFERENCE)

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, AstraZeneca PLC -- Conferences, meetings and seminars, Sanofi S.A. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, American Association for Cancer Research -- Conferences, meetings and seminars
Abstract

Dec 11, 2010 (TheFlyOnTheWall.com via COMTEX) -- CONFERENCES - 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM 12/12/10 (5 DAY CONFERENCE) Managers: Cancer Therapy & Research Center Location: Henry B. [...]

Published
2010

27. CONFERENCES: 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM - 12/12/10 (5 DAY CONFERENCE)

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, AstraZeneca PLC -- Conferences, meetings and seminars, Sanofi S.A. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, American Association for Cancer Research -- Conferences, meetings and seminars
Abstract

Dec 10, 2010 (TheFlyOnTheWall.com via COMTEX) -- CONFERENCES - 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM 12/12/10 (5 DAY CONFERENCE) Managers: Cancer Therapy & Research Center Location: Henry B. [...]

Published
2010

28. CONFERENCES: 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM - 12/12/10 (5 DAY CONFERENCE)

Subjects
Sanofi S.A. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, American Association for Cancer Research -- Conferences, meetings and seminars
Abstract

Dec 10, 2010 (TheFlyOnTheWall.com via COMTEX) -- CONFERENCES - 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM 12/12/10 (5 DAY CONFERENCE) Managers: Cancer Therapy & Research Center Location: Henry B. [...]

Published
2010

29. CONFERENCES: 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM - 12/8/10 (5 DAY CONFERENCE)

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, American Association for Cancer Research -- Conferences, meetings and seminars
Abstract

Dec 09, 2010 (TheFlyOnTheWall.com via COMTEX) -- CONFERENCES - 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM 12/8/10 (5 DAY CONFERENCE) Managers: Cancer Therapy & Research Center Location: Henry B. [...]

Published
2010

30. CONFERENCES: 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM - 12/8/10 (5 DAY CONFERENCE)

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, American Association for Cancer Research -- Conferences, meetings and seminars
Abstract

Dec 08, 2010 (TheFlyOnTheWall.com via COMTEX) -- CONFERENCES - 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM 12/8/10 (5 DAY CONFERENCE) Managers: Cancer Therapy & Research Center Location: Henry B. [...]

Published
2010

31. CONFERENCES: 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM - 12/8/10 (5 DAY CONFERENCE)

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, American Association for Cancer Research -- Conferences, meetings and seminars
Abstract

Dec 07, 2010 (TheFlyOnTheWall.com via COMTEX) -- CONFERENCES - 33RD ANNUAL CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM 12/8/10 (5 DAY CONFERENCE) Managers: Cancer Therapy & Research Center Location: Henry B. [...]

Published
2010

32. Data Presented at the AACR -- IASLC Conference on the Molecular Origins of Lung Cancer Demonstrate Lower Rates of T790M-Mediated Resistance With XL647 Than With Other EGFR Tyrosine Kinase Inhibitors

Subjects
Oncology, Experimental -- Conferences, meetings and seminars, Tyrosine -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Phenols -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Research, Lung cancer -- Conferences, meetings and seminars -- Drug therapy, Epidermal growth factor -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

Byline: Staff Jan 13, 2010 (GlobeNewswire via COMTEX) -- Preclinical Studies Show No Emergence of EGFR T790M Mutations With XL647 in EGFR-Mutated Lung Cancer; Lower Than Expected Mutation Rate Also [...]

Published
2010

33. Infinity Announces Updated Presentation Time at the J.P. Morgan Healthcare Conference

Subjects
JPMorgan Chase & Co. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Banking industry -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Cancer -- Care and treatment, Antimitotic agents -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Health care industry, Banking industry, Banking, finance and accounting industries, Business
Abstract

Byline: Staff CAMBRIDGE, Mass., Jan 11, 2010 (GlobeNewswire via COMTEX) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the company has an updated [...]

Published
2010

34. Infinity Announces Presentations at January Conferences

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Care and treatment, Antimitotic agents -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

Byline: Staff CAMBRIDGE, Mass., Jan 7, 2010 (GlobeNewswire via COMTEX) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that presentations will be made [...]

Published
2010

35. Basilea presents new research data on oncology drug candidate BAL27862 at international cancer conference

Subjects
Oncology, Experimental -- Conferences, meetings and seminars -- Drug therapy, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Conferences, meetings and seminars -- Drug therapy -- Research, Antimitotic agents -- Conferences, meetings and seminars
Abstract

BASEL, SWITZERLAND, Nov 19, 2009 (MARKETWIRE via COMTEX) -- Basilea Pharmaceutica Ltd. (SWISS: BSLN) presents new research data on its innovative antitumor drug candidate BAL27862 at the international conference on […]

Published
2009

36. Epistem Presents Further Data Supporting Its Plucked Hair Biomarker Technology at the Institute of Cancer Research Centenary Conference; Data on the effects of gemcitabine on epithelial tissue released

Subjects
Oncology, Experimental -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Conferences, meetings and seminars -- Research, Antimitotic agents -- Conferences, meetings and seminars
Abstract

MANCHESTER, UNITED KINGDOM, Jun 02, 2009 (MARKETWIRE via COMTEX) -- Epistem plc (LSE: EHP), the UK biotechnology and contract research company, will present preclinical results from its recently completed plucked […]

Published
2009

37. BSD Medical Corp.: Lecture At Surgical Oncology Conference Reports Near Doubling of Disease-Free Survival When Hyperthermia Therapy Was Added to Chemotherapy in Treating Sarcoma Cancer Patients

Subjects
BSD Medical Corp. -- Conferences, meetings and seminars, Medical equipment and supplies industry -- Conferences, meetings and seminars, Medical test kit industry -- Conferences, meetings and seminars, Chemotherapy -- Conferences, meetings and seminars, Sarcoma -- Conferences, meetings and seminars, Sarcoma -- Patient outcomes, Sarcoma -- Care and treatment, Medical research -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Cancer patients -- Conferences, meetings and seminars, Cancer patients -- Patient outcomes, Cancer patients -- Care and treatment, Antimitotic agents -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Chemotherapy, Cancer -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

SALT LAKE CITY, Mar 12, 2009 (GlobeNewswire via COMTEX) -- BSD Medical Corp. (Nasdaq:BSDM) announced today that Professor Rolf Issels, M.D. Ph.D. of the Munich University Medical School in Germany [...]

Published
2009

38. Chemokine Therapeutics Announces Three Posters Presented on Its Lead Compound, CTCE-9908, at the 2008 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Conference

Subjects
European Organization for Research and Treatment of Cancer -- Conferences, meetings and seminars, American Association for Cancer Research -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Conferences, meetings and seminars -- Research, Antimitotic agents -- Conferences, meetings and seminars
Abstract

VANCOUVER, BRITISH COLUMBIA, Oct 28, 2008 (MARKET WIRE via COMTEX) -- Chemokine Therapeutics Corp. ('Chemokine Therapeutics' or the 'Company') (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat […]

Published
2008

39. AngioChem's ANG1005 Demonstrates Preliminary Clinical Safety and Tolerability in Brain Cancer Patients; Data Presented at EORTC-NCI-AACR Symposium Validates Blood Brain Barrier Vector Technology

Subjects
Cancer patients -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Cancer -- Care and treatment, Brain cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars
Abstract

MONTREAL, CANADA AND GENEVA, SWITZERLAND, Oct 22, 2008 (MARKET WIRE via COMTEX) -- AngioChem, Inc., a clinical-stage biotechnology company dedicated to creating and developing new drugs to treat brain diseases, […]

Published
2008

40. Dr. Michael Nobel Delivers Keynote Address On Hyperthermia Therapy At Japanese Cancer Symposium

Subjects
BSD Medical Corp. -- Conferences, meetings and seminars, Medical equipment and supplies industry -- Conferences, meetings and seminars, Medical equipment and supplies industry -- Health aspects, Medical test kit industry -- Conferences, meetings and seminars, Medical test kit industry -- Health aspects, Antimitotic agents -- Conferences, meetings and seminars, Antimitotic agents -- Health aspects, Antineoplastic agents -- Conferences, meetings and seminars, Antineoplastic agents -- Health aspects, Oncology, Experimental -- Conferences, meetings and seminars, Oncology, Experimental -- Health aspects, Cancer -- Conferences, meetings and seminars, Cancer -- Health aspects, Cancer -- Care and treatment, Cancer -- Research, Banking, finance and accounting industries, Business
Abstract

SALT LAKE CITY, Oct 14, 2008 (GlobeNewswire via COMTEX) -- BSD Medical Corporation (Nasdaq:BSDM) announced today that a member of its Board of Directors, Dr. Michael Nobel, was the keynote [...]

Published
2008

41. Immunomedics' Product Candidates Being Presented At 2008 American Association for Cancer Research Annual Meeting

Subjects
Immunomedics Inc. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Conferences, meetings and seminars -- Research, Monoclonal antibodies -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

Byline: Staff MORRIS PLAINS, N.J., Apr 10, 2008 (PrimeNewswire via COMTEX) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, [...]

Published
2008

42. MethylGene Reports MGCD0103 Clinical Data at the 2008 Gastrointestinal Cancers Symposium; Data from Phase I/II MGCD0103 combination trial with Gemzar(R) in patients with solid tumors

Subjects
Pharmion Corp. -- Conferences, meetings and seminars, MethylGene Inc. -- Conferences, meetings and seminars, Gemzar (Medication), Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars
Abstract

MONTREAL, QUEBEC, Jan 28, 2008 (MARKET WIRE via COMTEX) -- MethylGene Inc. (TSX: MYG), along with its collaborator Pharmion Corporation (NASDAQ: PHRM), today updated clinical data from the Companies' MGCD0103 […]

Published
2008

43. Infinity Announces Updated Presentation Time At the JPMorgan Healthcare Conference

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Health care industry, Banking, finance and accounting industries, Business
Abstract

Byline: Staff CAMBRIDGE, Mass., Jan 3, 2008 (PrimeNewswire via COMTEX) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced an updated presentation time at [...]

Published
2008

44. Immunomedics Announces Outcome of 2007 Annual Meeting of Shareholders

Subjects
Ernst & Young L.L.P. -- Conferences, meetings and seminars, Immunomedics Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Care and treatment, Accounting firms -- Conferences, meetings and seminars, Stockholders -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

Byline: Staff MORRIS PLAINS, N.J., Dec 5, 2007 (PrimeNewswire via COMTEX) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, [...]

Published
2007

45. MethylGene and Pharmion Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference; - Safety and response data from Phase I/II MGCD0103 combination trial with Gemzar(R) in patients with solid tumors presented

Subjects
Pharmion Corp. -- Conferences, meetings and seminars, MethylGene Inc. -- Conferences, meetings and seminars, Gemzar (Medication), Tumors -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Cancer -- Care and treatment, Clinical trials -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars
Abstract

MONTREAL, QUEBEC AND BOULDER, COLORADO, Oct 24, 2007 (MARKET WIRE via COMTEX) -- MethylGene Inc. (TSX: MYG) and Pharmion Corporation (NASDAQ: PHRM) today reported preliminary clinical data from the Companies' […]

Published
2007

46. Novacea to Webcast Presentation at the Bear Stearns Healthcare Conference

Subjects
Health care industry, Securities industry, Bear Stearns Companies Inc. -- Conferences, meetings and seminars, Novacea Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars
Abstract

SOUTH SAN FRANCISCO, CA, Sep 06, 2007 (MARKET WIRE via COMTEX) -- Novacea, Inc. (NASDAQ: NOVC) today announced that Edward C. Albini, the company's chief financial officer, will be presenting […]

Published
2007

47. Positive survival data from ASA404 trial presented at World Conference on Lung Cancer

Subjects
Antisoma PLC -- Conferences, meetings and seminars, Respiratory tract diseases -- Conferences, meetings and seminars, Cancer patients -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Lung cancer, Non-small cell -- Conferences, meetings and seminars, Chemotherapy -- Conferences, meetings and seminars, Cancer -- Chemotherapy, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars
Abstract

SEOUL, SOUTH KOREA and LONDON, Sep 05, 2007 (MARKET WIRE via COMTEX) -- Seoul, South Korea, and London, UK: 5 September 2007 - Cancer drug developer Antisoma plc (LSE: ASM, […]

Published
2007

48. Data From Adherex's European Phase Ib/II Trial of ADH-1 to be Presented at International Symposium on Targeted Anticancer Therapies

Subjects
Adherex Technologies Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Cancer -- Care and treatment, Clinical trials -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars
Abstract

RESEARCH TRIANGLE PARK, NORTH CAROLINA, Mar 08, 2007 (MARKET WIRE via COMTEX) -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under […]

Published
2007

49. Micromet Reports on First International Symposium on EpCAM Biology and Clinical Application

Subjects
Micromet Inc. -- Conferences, meetings and seminars, Biological products -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Care and treatment, Antimitotic agents -- Conferences, meetings and seminars
Abstract

CARLSBAD, CA, Jan 29, 2007 (MARKET WIRE via COMTEX) -- Meeting review published in British Journal of Cancer supports EpCAM (CD326) as prime target for cancer therapy Carlsbad, CA, January […]

Published
2007

50. Infinity Presentation At the JPMorgan Healthcare Conference Rescheduled to Monday, January 8, 2007 At 8:00 a.m. PST

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Health care industry, Banking, finance and accounting industries, Business
Abstract

Byline: Staff CAMBRIDGE, Mass., Jan 4, 2007 (PrimeNewswire via COMTEX) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), today announced that the company's presentation at the 25th Annual JPMorgan Healthcare Conference has been [...]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results